UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified Huntington’s Disease Rating Scale, and neurofilament light chain levels to support the accelerated approval of its gene therapy AMT-130.
4hon MSN
An intellectually active lifestyle—in other words, the so-called cognitive reserve—has a protective effect on the progression and severity of the symptoms of motor, cognitive and psychiatric ...
Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...
A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the ...
News Medical on MSN8d
Heart medication may slow the progression of Huntington's diseaseResearch indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
MedPage Today on MSN9d
Beta-Blockers Tied to Delayed Huntington's Disease ProgressionThe disease is characterized by progressive motor, cognitive, and psychiatric decline. Three treatments are approved to treat ...
A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback